Atlas Trials

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Clinical trial NCT01519427 · TERMINATED

Trial details

NCT number
NCT01519427
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
Start date
2012-01-01
Primary completion
2013-05-01
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.